Inclusion Criteria:

          -  EGFR mutation positive Non-Small Cell lung cancer (NSCLC) (regardless of smoking
             status), or control group may encompass other molecular subtypes of lung cancer e.g.
             anaplastic lymphoma kinase (ALK) and Kirsten rat sarcoma viral oncogene homolog
             (KRAS).

          -  All early stage patients with NSCLC who are deemed surgically resectable.

          -  All patients must have histologically proven NSCLC, with known EGFR mutation

          -  Patients should be fit for either lobectomy/ pneumonectomy with or without lymph node
             sampling.

          -  Primary tumour should be at least 2 cm in size (Tumor stage 1b).

          -  Willing to provide informed consent.

        Exclusion Criteria:

          -  Known severe hypersensitivity to gefitinib or any of the excipients of this product

          -  Any serious concomitant systemic disorder that, in the opinion of the investigator,
             would compromise the patient's ability to complete the study.

          -  Interstitial lung disease (ILD) or pulmonary fibrosis; impaired pulmonary function

          -  Patients with prior exposure to agents directed at the Human epidermal receptor (HER)
             axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).

          -  Patients with prior exposure to chemotherapy, irradiation or systemic anti-cancer
             therapy (e.g. monoclonal antibody therapy) for lung cancer.

          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, myocardial infarction within six months,
             serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic
             disease).

          -  Evidence of any other disease, neurological or metabolic dysfunction, physical
             examination or laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates the use of an investigational drug or puts the subject
             at high risk for treatment-related complications.

          -  Patient who has serious active infection.

          -  Patients who harbouring exon 20 T(Threonine)790M (Methionine) mutation.

          -  Pregnancy or breast feeding.